Circulating tumor DNA (ctDNA) clearance as a biomarker in patients with locally advanced NSCLC following chemoradiation Read more about Circulating tumor DNA (ctDNA) clearance as a biomarker in patients with locally advanced NSCLC following chemoradiation
Resistance mechanisms to BRAF inhibition identified by single circulating tumor cell and cell-free tumor DNA molecular profiling in BRAF-mutant non-small-cell lung cancer Read more about Resistance mechanisms to BRAF inhibition identified by single circulating tumor cell and cell-free tumor DNA molecular profiling in BRAF-mutant non-small-cell lung cancer
Residual ctDNA after treatment predicts early relapse in patients with early stage non-small cell lung cancer Read more about Residual ctDNA after treatment predicts early relapse in patients with early stage non-small cell lung cancer
Real time clinical utility of ctDNA genomic alterations in untreated patients with advanced NSCLC Read more about Real time clinical utility of ctDNA genomic alterations in untreated patients with advanced NSCLC
Plasma first: Accelerating lung cancer diagnosis through liquid biopsy Read more about Plasma first: Accelerating lung cancer diagnosis through liquid biopsy
ctDNA dynamics in early stage node negative non-small cell lung cancers Read more about ctDNA dynamics in early stage node negative non-small cell lung cancers
Validation of recurrence prediction using circulating tumor DNA in patients with curatively treated early stage non-small cell lung cancer Read more about Validation of recurrence prediction using circulating tumor DNA in patients with curatively treated early stage non-small cell lung cancer
LIBELULE: A randomized phase III study to evaluate the clinical relevance of early liquid biopsy (LB) in patients with suspicious metastatic lung cancer Read more about LIBELULE: A randomized phase III study to evaluate the clinical relevance of early liquid biopsy (LB) in patients with suspicious metastatic lung cancer
Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer Read more about Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer
Circulating tumor DNA analysis for patients with oncogene-addicted NSCLC with isolated central nervous system progression Read more about Circulating tumor DNA analysis for patients with oncogene-addicted NSCLC with isolated central nervous system progression